MX2022011712A - Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. - Google Patents

Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.

Info

Publication number
MX2022011712A
MX2022011712A MX2022011712A MX2022011712A MX2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A MX 2022011712 A MX2022011712 A MX 2022011712A
Authority
MX
Mexico
Prior art keywords
mrgpr
mas
modulators
methods
compounds
Prior art date
Application number
MX2022011712A
Other languages
English (en)
Inventor
Esther Martinborough
Liming Huang
Adam Yeager
Brandon Selfridge
Marcos Sainz
Marcus Boehm
Original Assignee
Escient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escient Pharmaceuticals Inc filed Critical Escient Pharmaceuticals Inc
Publication of MX2022011712A publication Critical patent/MX2022011712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan en general métodos para modular el MRGPR X4, o para tratar una condición dependiente del MRGPR X4 de manera más específica, al poner en contacto el MRGPR X4 o administrar a un sujeto necesitado de los mismos, respectivamente, una cantidad efectiva de un compuesto que tiene la estructura de la Fórmula (I): (ver Fórmula) o un isómero, racemato, hidrato, solvato, isótopo o sal farmacéuticamente aceptable del mismo, en donde m, n, p, t, A, B, Z, R1, R2 y R3 son como se define en este documento. También se proporcionan composiciones farmacéuticas que contienen estos compuestos, así como también los compuestos mismos. Los moduladores de la proteína G relacionada con Mas (MRGPR) X4, son en particular isoindolinonas e isoquinolinonas sustituidas en el anillo carbocíclico. Los compuestos son útiles para tratar condiciones asociadas con la comezón, condiciones asociadas con el dolor o un trastorno autoinmune.
MX2022011712A 2020-04-17 2021-04-15 Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados. MX2022011712A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011964P 2020-04-17 2020-04-17
PCT/US2021/027477 WO2021211839A1 (en) 2020-04-17 2021-04-15 Modulators of mas-related g-protein receptor x4 and related products and methods

Publications (1)

Publication Number Publication Date
MX2022011712A true MX2022011712A (es) 2022-10-07

Family

ID=75787327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011712A MX2022011712A (es) 2020-04-17 2021-04-15 Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.

Country Status (11)

Country Link
US (1) US11787767B2 (es)
EP (1) EP4135691A1 (es)
JP (1) JP2023523545A (es)
KR (1) KR20230004493A (es)
CN (1) CN115397412A (es)
AU (1) AU2021255966A1 (es)
BR (1) BR112022018001A2 (es)
CA (1) CA3170064A1 (es)
IL (1) IL297139A (es)
MX (1) MX2022011712A (es)
WO (1) WO2021211839A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236920A1 (en) * 2022-06-07 2023-12-14 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
WO2024083210A1 (en) * 2022-10-21 2024-04-25 Hepaitech (Beijing) Biopharma Technology Co., Ltd. Compounds, compositions and methods thereof
WO2024098210A1 (zh) * 2022-11-07 2024-05-16 深圳博瑞医药科技有限公司 一种芳基羧酸类化合物及其制备Mrgpr X4抑制剂的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
BR9709906A (pt) 1996-06-17 1999-08-10 Smithkline Beecham Plc Derivados de benzamida substituídos e o uso dos mesmos como anticonvulsivantes
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
WO2001091796A2 (en) * 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
AR065810A1 (es) * 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
US10383868B2 (en) 2015-11-28 2019-08-20 Russell Dahl Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
WO2017133258A1 (zh) 2016-02-04 2017-08-10 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107033087B (zh) 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
KR20180134860A (ko) * 2016-02-15 2018-12-19 체엠엠 - 포르슝스첸트룸 퓨어 몰레쿨라레 메디친 게엠베하 암의 치료를 위한 taf1 억제제
CN108689937B (zh) 2017-04-10 2021-09-17 西华大学 吲唑类化合物及其在制备ido抑制剂类药物上的用途
AU2018301335B2 (en) * 2017-07-10 2022-09-15 Celgene Corporation Antiproliferative compounds and methods of use thereof
AU2019211383A1 (en) * 2018-01-25 2020-06-11 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation
KR102114389B1 (ko) 2018-05-02 2020-05-25 이화여자대학교 산학협력단 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
CN108863892B (zh) 2018-07-04 2022-04-05 温州医科大学 一种含酰胺结构的没食子酸甲酯类似物及应用
CN110903224A (zh) 2018-09-18 2020-03-24 复旦大学 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途
AU2020244855A1 (en) 2019-03-28 2021-11-18 Escient Pharmaceuticals, Inc. Modulators of Mas-related G-protein receptor X4 and related products and methods
US20220251043A1 (en) 2019-07-23 2022-08-11 Taipei Medical University Histone deacetylase 6 inhibitors and method for treating neuropathic pain

Also Published As

Publication number Publication date
EP4135691A1 (en) 2023-02-22
US11787767B2 (en) 2023-10-17
KR20230004493A (ko) 2023-01-06
WO2021211839A1 (en) 2021-10-21
CN115397412A (zh) 2022-11-25
CA3170064A1 (en) 2021-10-21
BR112022018001A2 (pt) 2022-11-08
IL297139A (en) 2022-12-01
US20210340106A1 (en) 2021-11-04
JP2023523545A (ja) 2023-06-06
AU2021255966A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2022011712A (es) Moduladores de receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
EA202091930A1 (ru) Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления
CR20200588A (es) Compuestos novedosos
EA201991403A1 (ru) Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
MX2023007192A (es) Inhibidores de prmt5.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
WO2022061008A3 (en) Modulators of mas-related g-protein receptor x4 and related products and methods
AU2013301914A8 (en) Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR gamma
MX344701B (es) Derivados de pirrol como moduladores de nachr alfa 7.
PH12019502562A1 (en) N-substituted indole derivatives
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
PH12021550549A1 (en) Dp antagonist
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023003476A (es) Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.
BR112023022050A2 (pt) Agonistas do receptor de orexina e usos destes
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
ZA202206266B (en) Pd-l1 antagonist compound